Edition:
United Kingdom

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

0.14USD
20 Feb 2018
Change (% chg)

$-0.01 (-4.33%)
Prev Close
$0.15
Open
$0.15
Day's High
$0.15
Day's Low
$0.14
Volume
791,506
Avg. Vol
669,712
52-wk High
$1.52
52-wk Low
$0.11

Chart for

About

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuti... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $14.22
Shares Outstanding(Mil.): 67.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Jaguar Health Files For Resale Or Other Disposition Of Up To 6.02 Mln Shares Of Voting Common Stock

* JAGUAR HEALTH INC FILES FOR RESALE OR OTHER DISPOSITION OF UP TO 6.02 MILLION SHARES OF VOTING COMMON STOCK - SEC FILING Source text: [http://bit.ly/2BJoioW] Further company coverage:

31 Jan 2018

BRIEF-Jaguar Health Provides Updates Regarding Programs

* JAGUAR HEALTH PROVIDES UPDATES REGARDING COMMERCIAL, EDUCATIONAL & PRODUCT DEVELOPMENT PROGRAMS AND 2017 RESULTS FOR MYTESI SINCE MERGER (AUGUST–DECEMBER 2017) Source text for Eikon: Further company coverage:

22 Jan 2018

BRIEF-Jaguar Health Says Unit Entered Amendment To Note Purchase Agreement

* JAGUAR HEALTH - ON DEC 29, 2017, UNIT ENTERED AMENDMENT TO NOTE PURCHASE AGREEMENT & NOTES WITH EACH OF PURCHASERS PARTY TO AGREEMENT DATED MARCH 1, 2017

02 Jan 2018

BRIEF-Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​

* JAGUAR HEALTH INC - ‍ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA​

14 Dec 2017

BRIEF-Jaguar Health enters share purchase agreement

* JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC

27 Nov 2017

BRIEF-Jaguar Health ‍signs non-binding term sheet to issue note to Iliad Research

* Jaguar health enters non-binding agreement of terms to issue a secured convertible note to iliad research and trading, l.p. (an affiliate of chicago venture partners, l.p.), as jaguar expands commercial efforts for mytesi

08 Nov 2017

BRIEF-Jaguar Health enters into letter agreement with Maxim Group LLC

* Jaguar Health - ‍on Oct 25,co entered into letter agreement with Maxim Group LLC which amends certain terms of underwriting agreement dated Sept 29​ Source text : (http://bit.ly/2y8b9cc) Further company coverage:

26 Oct 2017

BRIEF-Jaguar Health files for resale or other disposition of up to 36 million shares of co

* Jaguar Health files for resale or other disposition of up to 36 million shares of co by the selling shareholders ‍​ Source text: (http://bit.ly/2gxkRxa) Further company coverage:

20 Oct 2017

BRIEF-Jaguar Health prices $4.25 million public offering of common stock

* Jaguar health prices $4.25 million public offering of common stock

29 Sep 2017

BRIEF-Jaguar unit Napo Pharmaceuticals files CMC supplement with FDA

* Jaguar subsidiary Napo Pharmaceuticals files CMC supplement with FDA for sample-size bottles of mytesi, Napo's FDA-approved human drug, to support upcoming national sample campaign Source text for Eikon: Further company coverage:

28 Sep 2017

Earnings vs. Estimates